Abstract
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with chronic kidney disease (CKD) identified as a significant risk factor. CKD is primarily monitored through the estimated glomerular filtration rate (eGFR), calculated using the CKD-EPI equation. Although epidemiological and clinical studies have consistently demonstrated strong associations between eGFR and CVDs, the genetic underpinnings of this relationship remain elusive. Recent genome-wide association studies (GWAS) have highlighted the polygenic nature of these conditions and identified several risk loci correlating with their cross-phenotypes. Nonetheless, the extent and pattern of their pleiotropic effects have yet to be fully elucidated. We analyzed the most comprehensive GWAS summary statistics, involving around 7.5 million individuals, to investigate the shared genetic architectures and the underlying mechanisms between eGFR and CVDs, focusing on single nucleotide polymorphisms (SNPs), genes, biological pathways, and proteins exhibiting pleiotropic effects. Our study identified 508 distinct genomic locations associated with pleiotropic effects across multiple traits, involving 379 unique genes, notably L3MBTL3 (6q23.1), MMP24 (20q11.22), and ABO (9q34.2). Additionally, pathways such as stem cell population maintenance and the glutathione metabolism pathway were pivotal in mediating the relationships between these traits. From the perspective of vertical pleiotropy, our findings suggest a causal relationship between eGFR and conditions such as atrial fibrillation and venous thromboembolism. These insights significantly enhance our understanding of the genetic links between eGFR and CVDs, potentially guiding the development of novel therapeutic strategies and improving the clinical management of these conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Natural Science Foundation of China Excellent Young Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and Applied Basic Research Foundation for Distinguished Young Scholars (Grant no. 24050000763), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research General Projects of Shenzhen Science and Technology Innovation Commission (Grant no. JCYJ20230807093514029) (To Y.F.), National Natural Science Foundation of China (Grant no. 82260073); Tianshan Talent Cultivation Program Project of Xinjiang Uygur Autonomous Region (Grant no. 2022TSYCLJ0028) (To Y.Y.), and Center for Computational Science and Engineering at Southern University of Science and Technology. The funder had no role in the design, implementation, analysis, interpretation of the data, approval of the manuscript, and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available GWAS summary statistics on estimated glomerular filtration rate and six major cardiovascular diseases that have originally been conducted using human data. GWAS summary statistics on eGFR are available at https://www.uni-regensburg.de/medizin/epidemiologie-praeventivmedizin/genetische-epidemiologie/gwas-summary-statistics/index.html. GWAS summary statistics on AF, HF, and Stroke are available at the GWAS Catalog (GCST90104539, GCST009541, and GCST90104539). GWAS summary statistics on CAD and PAD are publicly available for download at the Cardiovascular Disease Knowledge Portal (CVDKP) website: https://cvd.hugeamp.org/datasets.html. GWAS summary statistics on VTE are obtained from the deCODE genetics website: https://www.decode.com/summarydata/. Blood-based cis-pQTL from UKB-PPP are obtained from https://www.synapse.org/Synapse:syn51365303.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The study used only openly available GWAS summary statistics on estimated glomerular filtration rate and six major cardiovascular diseases that have originally been conducted using human data. GWAS summary statistics on eGFR are available at https://www.uni-regensburg.de/medizin/epidemiologie-praeventivmedizin/genetische-epidemiologie/gwas-summary-statistics/index.html. GWAS summary statistics on AF, HF, and Stroke are available at the GWAS Catalog (GCST90104539, GCST009541, and GCST90104539). GWAS summary statistics on CAD and PAD are publicly available for download at the Cardiovascular Disease Knowledge Portal (CVDKP) website: https://cvd.hugeamp.org/datasets.html. GWAS summary statistics on VTE are obtained from the deCODE genetics website: https://www.decode.com/summarydata/. Blood-based cis-pQTL from UKB-PPP are obtained from https://www.synapse.org/Synapse:syn51365303.
